Orencia: Try Again in Lupus? (CME/CE)
(MedPage Today) -- Benefits seen for articular symptoms
CONCLUSION: Improvements of DLE can be achieved with PDL. PMID: 29676592 [PubMed - as supplied by publisher]
Injections of the drug Belimumab, marketed as Benlysta, benefited patients with a form of lupus in a Phase 3 clinical trial, researchers reported this week.
(MedPage Today) -- Patients with concomitant Sjogren's syndrome improved with epratuzumab
Conditions: Lupus Erythematosus; Lupus Erythematosus, Systemic; Age Related Macular Degeneration Intervention: Procedure: Blood test Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Recruiting
(MedPage Today) -- Exclusive video with Susan Manzi, MD, Co-Director of the Lupus Center of Excellence at Allegheny Health Network and Jill Buyon, MD, Director of the Division of Rheumatology at NYU Langone Health.
First bit of news: I’ve had absolutely no pain in my heel. It’s as good as new. I have to admit I’m still stunned…and I wonder if a more conventional doctor, let’s say a physiotherapist, would have made the connection between my relatively new eyeglass prescription and my heel pain. I doubt it. This makes me wonder how many similar cases there are, of people who think they have plantar fasciitis or tendonitis or, sorry for the mention! , heel spurs, but whose pain actually originated in a different part of the body, an easy-to-fix part of the body. Mind-blowing, eh? But the reason I&rsq...
(Wiley) New research indicates that belimumab, a monoclonal antibody therapy that targets a component of the immune system, provides considerable benefits to patients with systemic lupus erythematosus (SLE), a predominately female, chronic inflammatory disease that can affect virtually any organ.
AbstractThe aim of this study is to assess the relationship between autoimmunity and endothelial activation/damage (ICAM-1 and vWF serum levels) and the degree of prothrombotic activity (thrombin –antithrombin complexes—TAT serum levels) in SLE. In 60 clinically stable SLE patients, levels of the following parameters were estimated in their serum: lupus anticoagulant (LA), anticardiolipin antibodies in both IgG and IgM classes (aCL-IgG and aCL-IgM, respectively), antiβ2GPI antibodies in both IgG and IgM classes (antiβ2GPI-IgG and antiβ2GPI-IgM, respectively), ICAM, von Willebrand factor (vWF), TA...
AbstractTo determine, among systemic lupus erythematosus patients, factors associated with active tuberculosis. We performed a case-control study, in a tertiary-care center in Mexico City. We defined cases as systemic lupus erythematosus patients with active tuberculosis and matched them 1:1 with systemic lupus erythematosus patients without tuberculosis (controls) by age, date of systemic lupus erythematosus diagnosis, and disease duration. We analyzed clinical variables, lupus disease activity (SLEDAI-2K), and accumulated damage (SLICC/ARC-DI). We performed a nonconditional logistic regression to determine factors associ...
Systemic lupus erythematosus (SLE) is a prototypic systemic autoimmune disease characterized by the loss of tolerance against nuclear autoantigens in which the production of autoantibodies leads to tissue damages through the formation and deposition of immune complexes. Recent genome-wide association studies of SLE patients have revealed that polymorphisms of interferon regulatory factor (IRF) 7 and IRF8 are associated with an increased risk of SLE but the precise role of these IRFs in SLE development is not fully understood.